Patrick H. Ruane
Chief Operating Officer Revanna Therapeutics
Seminars
Wednesday 28th January 2026
The Sustained Release of Biologics, Large, & Small Molecules with Novel Photo Crosslinked Biodegradable Technologies
10:30 am
- Transforming Anti-VEGF Delivery: How Re-Vana’s sustained-release technology could reduce injection frequency for patients with retinal diseases
- Innovation at the Interface of Science & Patient Care: The science behind ReVana’s biodegradable implants and why it matters for the future of ophthalmology, including novel sustained release therapeutics
- Opportunities for Collaboration & Impact: Where Re-Vana is today and the potential paths forward, clinical development, partnerships, and commercial strategy
Wednesday 28th January 2026
Panel Discussion: Market Reactogenicity & Trial Design: Balancing Scientific Integrity with Commercial Urgency for Injectables
2:00 pm
- Why does early recruitment remain a bottleneck, especially for injected therapies in conservative indications like glaucoma?
- How do we design devices and protocols for operators who aren’t traditionally trained in injection procedures? • How do we push back against unrealistic investor timelines and expectations for one-and-done cures?
- What happens when a formulation looks great in vitro but fails due to real-world hurdles like sterilization or inflammatory responses?
